Jonathan Gerber
Overview
Explore the profile of Jonathan Gerber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
485
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yarava A, Marshall C, Reichert D, Ye A, Khanal P, Robbins S, et al.
J Clin Transl Sci
. 2024 Dec;
8(1):e200.
PMID: 39655012
Introduction: In response to the COVID-19 pandemic, we rapidly implemented a plasma coordination center, within two months, to support transfusion for two outpatient randomized controlled trials. The center design was...
2.
Kennedy A, Patel S, Ramanathan M, Gerber J, cerny J
Ann Hematol
. 2024 Jan;
103(3):1031-1033.
PMID: 38195923
No abstract available.
3.
Able C, Stewart C, Gabrielson A, Overholt T, Banner S, Gilliam K, et al.
Urology
. 2023 Dec;
184:217-223.
PMID: 38043907
Objective: To evaluate trends in opioid prescribing rates following pediatric urologic surgery. Methods: We queried the TriNetX Research database for patients under age 18 who underwent one of seven common...
4.
Koon A, He J, Patel J, Morse A, Boseman V, Hamilton A, et al.
Pharmacogenomics
. 2023 Oct;
24(15):821-830.
PMID: 37846549
Intravenous pentamidine is used for prophylaxis against pneumonia, an infection seen in hematopoietic stem cell transplant recipients. Pentamidine is partially metabolized by , which is vulnerable to pharmacogenetic variation. This...
5.
Thomas E, Kennedy A, Walsh W, Carpentier M, Adeyinka H, Patel S, et al.
Front Public Health
. 2023 Jun;
11:1186350.
PMID: 37333537
The COVID-19 pandemic revolutionized cancer care delivery leading to rapid adoption of digital technology for telehealth in the United States. In this study, we describe telehealth utilization trends across the...
6.
Baksh S, Heath S, Fukuta Y, Shade D, Meisenberg B, Bloch E, et al.
J Infect Dis
. 2023 Feb;
227(11):1266-1273.
PMID: 36722044
Background: Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) reduces hospitalizations among outpatients treated early after symptom onset. It is unknown whether CCP reduces time to symptom resolution among outpatients. Methods:...
7.
Shoham S, Bloch E, Casadevall A, Hanley D, Lau B, Gebo K, et al.
Clin Infect Dis
. 2022 May;
76(3):e477-e486.
PMID: 35579509
Background: The efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent infection when administered before...
8.
How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?
Bloch E, Tobian A, Shoham S, Hanley D, Gniadek T, Cachay E, et al.
Transfusion
. 2022 Mar;
62(5):933-941.
PMID: 35352362
Convalescent plasma, collected from donors who have recovered from a pathogen of interest, has been used to treat infectious diseases, particularly in times of outbreak, when alternative therapies were unavailable....
9.
Lee D, Gerber J, Bhatia V, Janzen N, Austin P, Koh C, et al.
Int Neurourol J
. 2022 Jan;
25(4):355-363.
PMID: 34991305
Purpose: The aim of this study was to assess the performance of a mobile acoustic Uroflowmetry (UFM) application compared with standard UFM in the pediatric population. Methods: A mobile acoustic...
10.
Shoham S, Bloch E, Casadevall A, Hanley D, Lau B, Gebo K, et al.
medRxiv
. 2021 Dec;
PMID: 34931202
Background: The efficacy of SARS-CoV-2 convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. We hypothesized that CCP might prevent infection when administered before symptoms or laboratory...